P. vivax malaria Infections and Infestations Plasmodium vivax malaria
Conditions
Interventions
The main intervention will be a revised treatment algorithm for vivax malaria integrating tafenoquine and G6PD test before radical cure treatment of vivax malaria. Tafenoquine (TQ) 300 mg will be admi
+2 days) after treatment for all patients who received radical cure treatment. Patients will be evaluated for early signs of AHA during follow-up visits. In a subset of two facilities, two ancillary s
Sponsors
PATH
Eligibility
Sex/Gender
All
Age
6 Months to 100 Years
Inclusion criteria
Inclusion criteria: 1. Patient with a confirmed P. vivax infection 2. Patients providing informed consent or assent
Exclusion criteria
Exclusion criteria: 1. Unwilling to provide informed consent 2. Showing signs of severe infection (patients)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured using patient records at the end of the study: 1. Proportion of vivax patients that are correctly treated with RC based on the revised algorithm based on patient records during the study period 2. Proportion of HCPs that adhere to the revised RC algorithm as relevant to their role in the health system based on patient records during the study period | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured using patient records at the end of the study: 1. Proportion of non-eligible patients that receive Radical Cure (TQ&PQ) treatment 2. Proportion of patients experiencing acute haemolytic anaemia (AHA) during the follow-up period, proportion of all AHA identified by HCPs and total number of AHAs identified during the study 3. The extent to which health facilities have consistent process to evaluate pregnancy status and functioning referral system in place, including emergency transportation and access to blood transfusion in referral facilities, assessed from routine monitoring visit reports 4. Proportion of HCPs who are able to correctly identify 8AQ-related adverse events 5. Healthcare provider satisfaction with the training provided assessed through training evaluation questionnaire and qualitative methods; knowledge and skills regarding G6PD testing and radical cure treatment over time, as determined by a competency assessment 6. Number and frequency of supervisory visits conducted during the study duration per health facility, adherence to supervision Standard Operating Procedure (SOP), and proportion of HCP who received personal routine supervision in the past 6 months, assessed from health facilities routine monitoring visit reports and qualitative methods 7. Patients and health care provider perceptions of and experience with the new RC tools, as reported in interviews and focus group discussions 8. Total monetary cost of G6PD testing, tafenoquine, training sessions and G6PD diagnostic quality assurance 9. Per patient monetary cost of including G6PD testing and single-dose cure from the perspective of the health system 10. The total number of additional malaria infections reported by study participants who receive TQ during the follow-up period 11. The number of study participants who received TQ and presented again to the facility with an additional malaria infection during the follow-up period 12. The total number of malaria infections that are iden | — |
Countries
Ethiopia
Outcome results
None listed